Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Mar 5;2014(3):CD009270.
doi: 10.1002/14651858.CD009270.pub3.

Cannabinoids for epilepsy

David Gloss  1 , Barbara Vickrey
Affiliations
Meta-Analysis

Cannabinoids for epilepsy

David Gloss et al. Cochrane Database Syst Rev. .

Abstract

Background: Marijuana appears to have anti-epileptic effects in animals. It is not currently known if it is effective in patients with epilepsy. Some states in the United States of America have explicitly approved its use for epilepsy.

Objectives: To assess the efficacy and safety of cannabinoids when used as monotherapy or add-on treatment for people with epilepsy.

Search methods: We searched the Cochrane Epilepsy Group Specialized Register (9 September 2013), Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2013, Issue 8), MEDLINE (Ovid) (9 September 2013), ISI Web of Knowledge (9 September 2013), CINAHL (EBSCOhost) (9 September 2013), and ClinicalTrials.gov (9 September 2013). In addition, we included studies we personally knew about that were not found by the searches, as well as searched the references in the identified studies.

Selection criteria: Randomized controlled trials (RCTs) whether blinded or not.

Data collection and analysis: Two authors independently selected trials for inclusion and extracted the data. The primary outcome investigated was seizure freedom at one year or more, or three times the longest interseizure interval. Secondary outcomes included responder rate at six months or more, objective quality of life data, and adverse events.

Main results: We found four randomized trial reports that included a total of 48 patients, each of which used cannabidiol as the treatment agent. One report was an abstract and another was a letter to the editor. Anti-epileptic drugs were continued in all studies. Details of randomisation were not included in any study report. There was no investigation of whether the control and treatment participant groups were the same or different. All the reports were low quality.The four reports only answered the secondary outcome about adverse effects. None of the patients in the treatment groups suffered adverse effects.

Authors' conclusions: No reliable conclusions can be drawn at present regarding the efficacy of cannabinoids as a treatment for epilepsy. The dose of 200 to 300 mg daily of cannabidiol was safely administered to small numbers of patients generally for short periods of time, and so the safety of long term cannabidiol treatment cannot be reliably assessed.

PubMed Disclaimer

Conflict of interest statement

None known

Update of

References

References to studies included in this review

Ames 1985 {published data only}
    1. Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. South African Medical Journal 1985;69:14. - PubMed
Cunha 1980 {published data only}
    1. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21:175‐85. - PubMed
Mechoulam 1978 {published data only}
    1. Mechoulam R, Carlini EA. Toward drugs derived from cannabis. Naturwissenschaften 1978;65:174‐9. - PubMed
Trembly 1990 {published data only (unpublished sought but not used)}
    1. Trembly B, Sherman M. Double‐blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana '90 International Conference on Cannabis and Cannabinoids;1990 July 8‐11; Kolympari, Crete. International Association for Cannabinoid Medicines, 1990:section 2‐page 5.

References to studies excluded from this review

Brust 1992 {published data only}
    1. Brust JC, Ng SK, Hauser AW, Susser M. Marijuana use and the risk of new onset seizures. Transactions of the American Clinical and Climatological Association 1992;103:176‐81. - PMC - PubMed
Carlini 1981 {published data only}
    1. Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. Journal of Clinical Pharmacology 1981;21:417S‐27S. - PubMed
Consroe 1975 {published data only}
    1. Consroe PF, Wood GC, Bauschbaum H. Anticonvulsant nature of marihuana smoking. JAMA 1975;234:306‐7. - PubMed
Consroe 1992 {published data only (unpublished sought but not used)}
    1. Consroe PF, Sandyk R. Potential role of cannabinoid for therapy of neurological disorders. In: L Murphy, A Bartke editor(s). Maijuana/Cannabinoids Neurobiology and Neurophysiology. Boca Raton: CRC Press, 1992:459‐524.
Corral 2001 {published data only}
    1. Corral VL. Differential effects of medical marijuana based on strain and route of administration: a three‐year observational study. Journal of Cannabis Therapeutics 2001;1(3/4):43‐59.
Davis 1949 {published data only}
    1. Davis JP, Ramsey HH. Anti‐epileptic action of marijuana‐active substances. Federation Proceedings 1949;8:167.
Ellison 1990 {published data only}
    1. Ellison JM, Gelwan E, Ogletree J. Complex partial seizure symptoms affected by marijuana abuse. Journal of Clinical Psychiatry 1990;51(10):439‐40. - PubMed
Feeney 1976 {published data only}
    1. Feeney DM. Marihuana use among epileptics. JAMA 1976;235(11):1105. - PubMed
Gieringer 2002 {published data only}
    1. Gieringer D. Medical Use of Cannabis: Experience in California. In: F Grotenherman, E Russo editor(s). Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. New York, NY: The Haworth Press, 2002:143‐51.
Gordon 2001 {published data only}
    1. Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001;42(10):1266‐72. - PubMed
Grinspoon 1997 {published data only}
    1. Grinspoon L, Bakalar JB. Marihuana, the forbidden medicine. New Haven, CT: Yale University Press, 1997.
Gross 2004 {published data only}
    1. Gross DW, Hamm J, Ashowrth NL, Quigley D. Marijuana use and epilepsy. Neurology 2004;62:2095‐7. - PubMed
Grotenherman 2003 {published data only}
    1. Grotenherman F, Schnelle M. Survey on the Medical Use of Cannabis and THC in Germany. Journal of Cannabis Therapeutics 2003;3(2):17‐39.
Keeler 1967 {published data only}
    1. Keeler MH, Reifler CB. Grand mal convulsions subsequent to marijuana use. Case report. Diseases of the Nervous System 1967;28(7 Pt 1):474‐5. - PubMed
Lorenz 2003 {published data only}
    1. Lorenz R. Experiences with THC‐treatment in children and adolescents. IACM 2nd Conference on Cannabinoids in Medicine. Koeln, Germany: International Association for Cannabis as Medicine, 2003:6.
Lorenz 2004 {published data only}
    1. Lorenz R. On the application of cannabis in paediatrics and epileptology. Neuroendocrinology Letters 2004;25(1‐2):40‐4. - PubMed
Lutz 2008 {published data only}
    1. Lutz B, Monory K. Soothing the seizures of children. Nature Medicine 2008;14(7):721‐2. - PubMed
Mortati 2007 {published data only}
    1. Mortati K, Dworetzky B, Devinsky O. Marijuana: an effective treatment in partial epilepsy? A case report and review of the literature. Reviews in Neurological Diseases 2007;4(2):103‐6. - PubMed
Ng 1990 {published data only}
    1. Ng SKC, Brust JCM, Hauser WA, Susser M. Illicit drug use and the risk of new‐onset seizures. American Journal of Epidemiology 1990;132(1):47‐57. - PubMed
Perez‐Reyes 1974 {published data only}
    1. Perez‐Reyes M, Wingfield M. Cannabidiol and electroencephalographic epileptic activity. JAMA 1974;230(12):1635. - PubMed
Petro 1997 {published data only}
    1. Petro D. Seizure Disorders. In: ML Mathre editor(s). Cannabis in Medical Practive. Jefferson, NC: McFarland & Co, Inc., 1997:125‐8.
Pijlman 2005 {published data only}
    1. Pijlman FT, Rigter SM, Hoek J, Goldschmidt HM, Niesink RJ. Strong increase in total delta‐THC in cannabis preparations sold in Dutch coffee shops. Addiction Biology 2005;10:171‐80. - PubMed

Additional references

Annegers 1999
    1. Annegers JF, Dubinsky S, Coan SP, Newmark ME, Roht L. The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. Epilepsia 1999;40(4):502‐6. - PubMed
Buckmaster 1997
    1. Buckmaster PS, Dudek FE. Neuron loss, granule cell axon reorganization, and functional changes in the dentate gyrus of epileptic kainate‐treated rats. Journal of Comparative Neurology 1997;385(3):385‐404. - PubMed
Buckmaster 2002
    1. Buckmaster PS, Zhang GF, Yamawaki R. Axon sprouting in a model of temporal lobe epilepsy creates a predominantly excitatory feedback circuit. Journal of Neuroscience 2002;22(15):6650‐8. - PMC - PubMed
Dudek 1997
    1. Dudek FE, Spitz M. Hypothetical mechanisms for the cellular and neurophysiologic basis of secondary epileptogenesis: proposed role of synaptic reorganization. Journal of Clinical Neurophysiology 1997;14(2):90‐101. - PubMed
EMCDDA 2002
    1. European Monitoring Centre for Drugs and Drug Addiction. Medicinal cannabis and derivatives: a legal analysis of the options, their limitations, and current practice in the EU. www.eldd.emcdda.org/databases/eldd_comparative_analyses.cfm (date accessed March 15, 2011) 2002.
Feigenbaum 1989
    1. Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, et al. Nonpsychotropic cannabinoid as a functional N‐methy‐D‐aspartate receptor blocker. Proceedings of the National Academy of Sciences of the United States 1989;86(23):9584‐7. - PMC - PubMed
Felder 1998
    1. Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annual Review of Pharmacology and Toxicology 1998;38:179‐200. - PubMed
Franck 1995
    1. Franck AE, Pokorny J, Kunkel DD, Schwartzkroin PA. Physiologic and morphologic characteristics of granule cell circuitry in human epileptic hippocampus. Epilepsia 1995;36(6):543‐58. - PubMed
Gowers 1881
    1. Gowers WR. Epilepsy and Other Chronic Convulsive Disorders. London: Churchill, 1881.
Hauser 1993
    1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935‐1984. Epilepsia 1993;34(3):453‐68. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hoffman 2010
    1. Hoffman DE, Weber E. Medical marijuana and the law. New England Journal of Medicine 2010;362(16):1453‐6. - PubMed
Howlett 2004
    1. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004;47(S1):345‐58. - PubMed
Juul‐Jensen 1983
    1. Juul‐Jensen P, Foldspang A. Natural history of epileptic seizures. Epilepsia 1983;24(3):297‐312. - PubMed
Kirkham 2010
    1. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. - PubMed
Kwan 2000
    1. Kwan P, Brodie MJ. Early Identification of refractory epilepsy. New England Journal of Medicine 2000;342(5):314‐9. - PubMed
Kwan 2010
    1. Kwan P, Arzimanoglou A, Berg A, Brodie MJ, Hauser A, Mathern G, et al. Definition of drug resistant epilepsy: Consensus proposal of the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51(6):1069‐77. - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
MacDonald 2000
    1. MacDonald BK, Cockerell OC, Sander JWAS, Shorvon SD. The incidence and lifetime prevalence of neurologic disorders in a prospective community‐based study in the UK. Brain 2000;123(4):665‐75. - PubMed
Marsicano 2003
    1. Mariscano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, et al. CB1 cannabinoid receptors and on‐demand defense against excitotoxity. Science 2003;302(5642):84‐8. - PubMed
Matsuda 1990
    1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561‐4. - PubMed
Mechoulam 1970
    1. Mechoulam R. Marihuana chemistry. Science 1970;168(3936):1159‐66. - PubMed
Mechoulom 2007
    1. Mechoulom R, Peters M, Murillo‐Rodriguez E, Hanus LO. Cannabidiol ‐ recent advances. Chemistry and Biodiversity 2007;4(8):1678‐92. - PubMed
Mohanraj 2006
    1. Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. European Journal of Neurology 2006;13(3):277‐82. - PubMed
Munro 1993
    1. Munro S, Thomas KL, Abu‐Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365(6441):61‐5. - PubMed
Murray 1994
    1. Murray CJL, Lopez JD. Global Comparative Assessment in the Health Sector. 1st Edition. Geneva: World Health Organization, 1994.
Natasuka 2003
    1. Nakatsuka T, Chen H‐X, Roper SN, Gu JG. Cannabinoid receptor‐1 activation suppresses inhibitory synaptic activity in human dentate gyrus. Neuropharmacology 2003;45:116‐21. - PubMed
Olafsson 2005
    1. Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorffer D, Kjartansson O, Hauser WA. Incidence of unprovoked seizures and epilepsy in Iceland and an assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurology 2005;4(10):627‐34. - PubMed
Prevost 2000
    1. Prevost TC, Abrams KR, Jones DR. Models in generalized synthesis of evidence: an example based on studies of breast cancer screening. Statistics in Medicine 2000;19:3359‐76. - PubMed
Radwan 2009
    1. Radwan MM, Elsohly MA, Slade D, Ahmed SA, Khan IA, Ross SA. Biologically active cannabinoids from high‐potency Cannabis sativa. Journal of Natural Products 2009;72:906‐11. - PMC - PubMed
Razdan 1983
    1. Razdan RJ, Howes JF. Drugs related to tetrahydrocannabinol. Medicinal Research Reviews 1983;3(2):119‐46. - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Song 1993
    1. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, et al. Selective serotonin reuptake inhibitors: meta‐analysis of efficacy and acceptability. BMJ 1993;306:683‐7. - PMC - PubMed
Sutula 1989
    1. Sutula T, Cascino G, Cavazos C, Parada I, Ramirez L. Mossy fiber synaptic reorganization in the epileptic human temporal lobe. Annals of Neurology 1989;26(3):321‐30. - PubMed
Wilson 2001
    1. Wilson RE, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001;410(6828):588‐92. - PubMed
Winokur 2004
    1. Winokur RS, Kubal T, Liu D, Davis SF, Smith BN. Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy. Epilepsy Research 2004;58(2‐3):93‐105. - PubMed

References to other published versions of this review

Gloss 2012
    1. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD009270.pub2] - DOI - PubMed

MeSH terms